ENGINEERING NEXT-GENERATION CANCER IMMUNOTHERAPIES, SAN DIEGO, JANUARY 14-15, 2019
It has now been seven years since the first approval of ipilimumab, and there are now six mainstream checkpoint inhibitors approved for a range of cancers. Based on these clinical successes, the industry is now directing its attention to combination treatments, single agent therapeutics with multiple modes of action, confronting resistance mechanisms, reducing toxicity and the persistent challenge of solid tumors. Cambridge Healthtech Institute’s 5th Annual Engineering Next-Generation Cancer Immunotherapies provides a forum in which research scientists can discuss the contributions of protein engineering to the discovery and development of novel biotherapeutics in the oncology space.
With the recent advances in cancer immunotherapy, it is evident that the antigen-specific activation of the patients’ immune responses can be utilized for achieving significant therapeutic benefits. Despite the success of monoclonal antibodies against immune checkpoints, other therapeutic modalities are being applied to address many challenges of the biology of the tumor microenvironment. The potential of these agents as monotherapy or in combination with immune checkpoint inhibitors will be highlighted.
This presentation will outline recent efforts at UCSF to apply omics technologies and phage display to identify and target with recombinant human antibodies cell surface antigens that are upregulated by important oncogenic drivers. Recent screening efforts have identified new antibodies against cell surface proteins upregulated by mutant KRAS, c-MYC, and mTORC1, and the antibodies have been further matured for nuclear medicine applications like PET imaging and radioimmunotherapy.
ENGINEERING NEXT-GENERATION CANCER IMMUNOTHERAPIES, SAN DIEGO, JANUARY 08-09, 2018
A succession of strong clinical successes with antibodies against checkpoint targets has spawned a surge of interest from across the industry in the development of antibody immunotherapeutics and treatment combinations. The major challenges facing those now entering the field include establishing clinical proof of concept, product and target differentiation, selection of patient responders and the rational design of effective immunotherapy combinations. Cambridge Healthtech Institute’s Fourth Annual Engineering Next-Generation Cancer Immunotherapies offers presentations of protein engineering strategies to improve the efficacy of immunotherapeutics and drive the progress of more personalized treatments in this space.
This event will take place at Hilton San Diego Bayfront, 1 Park Blvd, San Diego, California.